
               
               
               7 DRUG INTERACTIONS
               
                  Drug-drug interaction studies have not been conducted with VIGAMOXÂ® solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.
               
               
            
         